Associations between Breast Cancer Susceptibility Gene Polymorphisms and Clinicopathological Features

Purpose: Genetic polymorphisms may affect not only cancer development but also cancer progression, and as a result could influence cancer phenotypes. The aim of this study was to examine the relationship between breast cancer susceptibility gene polymorphisms and clinicopathological features. Experimental Design: We genotyped 664 Korean primary breast cancer patients for 17 single-nucleotide polymorphisms (SNPs) in nine genes, using a high-throughput SNP scoring method. Results: CYP1A1 codon 462 Ile/Val or Val/Val variants and the CYP1B1 codon 432 Leu/Val variant were found more in breast cancer patients ≤35 years of age at onset than the common homozygote [odds ratio (OR), 1.6 and 1.7, respectively]. In combination analysis of these two SNPs, the OR was 1.9 when one of them was heterozygous or a rare homozygous form, and increased to 2.3 when both were variants (P = 0.006). Cases with Ile/Val at CYP1A1 codon 462 were 2.6-fold and those with Val/Val were 5.1-fold more likely to have first-degree relatives with breast cancer than those with Ile/Ile (P = 0.002). In the haplotype study of BRCA1, the 2430C/2731T/3667G/4427C/4956G homozygote showed less estrogen receptor negativity than the most common diplotype (OR, 0.5; 95% confidence interval, 0.26–0.94). TP53 codon 72 Arg/Pro or Pro/Pro variants were associated with negative axillary lymph node status (OR, 0.7; 95% confidence interval, 0.49–0.94). Conclusions: These results indicate that polymorphisms of some selected breast cancer susceptibility genes are associated with the clinicopathological phenotypes of breast cancer.

[1]  D. Noh,et al.  Reproductive Factors, Glutathione S-Transferase M1 and T1 Genetic Polymorphism and Breast Cancer Risk , 2003, Breast Cancer Research and Treatment.

[2]  D. Noh,et al.  Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women , 2003, British Journal of Cancer.

[3]  L. Hutchins,et al.  Association between a glutathione S‐transferase A1 promoter polymorphism and survival after breast cancer treatment , 2003, International journal of cancer.

[4]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[5]  W. Han,et al.  Role of alcohol and genetic polymorphisms of CYP2E1 and ALDH2 in breast cancer development. , 2003, Pharmacogenetics.

[6]  L. Hutchins,et al.  Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. , 2002, Journal of the National Cancer Institute.

[7]  B. Ponder,et al.  Effect of germ-line genetic variation on breast cancer survival in a population-based study. , 2002, Cancer research.

[8]  Qifeng Yang,et al.  Correlation of prostate-specific antigen promoter polymorphisms with clinicopathological characteristics in breast cancer. , 2002, Anticancer research.

[9]  E. Berns,et al.  Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. , 2002, Carcinogenesis.

[10]  Zhaohui S. Qin,et al.  Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. , 2002, American journal of human genetics.

[11]  M. Spitz,et al.  Sensitivity to benzo(a)pyrene diol-epoxide associated with risk of breast cancer in young women and modulation by glutathione S-transferase polymorphisms: a case-control study. , 2001, Cancer research.

[12]  L. Hutchins,et al.  Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. , 2001, Cancer research.

[13]  D. Noh,et al.  Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. , 2001, Pharmacogenetics.

[14]  A. Scorilas,et al.  Codon 89 polymorphism in the human 5 α -reductase gene in primary breast cancer , 2001, British Journal of Cancer.

[15]  H. Adami,et al.  Estrogen Receptor Gene Polymorphisms and Breast Cancer Risk , 2000 .

[16]  L. Hutchins,et al.  Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. , 2000, Cancer research.

[17]  D. Noh,et al.  Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. , 2000, Pharmacogenetics.

[18]  S. Culine,et al.  Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. , 2000, Cancer research.

[19]  X. Shu,et al.  Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  Anglian Breast Cancer Study Group.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000 .

[21]  M. Gentile,et al.  Association between CYP17 gene polymorphism and risk of breast cancer in young women , 1999, International journal of cancer.

[22]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[23]  E. Mariman,et al.  Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2 , 1999, British Journal of Cancer.

[24]  N. Roodi,et al.  Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. , 1998, Cancer research.

[25]  L. Norton,et al.  BRCA-associated breast cancer in young women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Willett,et al.  Cigarette smoking, cytochrome P450 1A1 polymorphisms, and breast cancer risk in the Nurses' Health Study. , 1998, Cancer research.

[27]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[28]  S. Pacini,et al.  Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. , 1998, Oncology research.

[29]  G. Hallmans,et al.  p53 polymorphisms and haplotypes in breast cancer. , 1996, Carcinogenesis.

[30]  D. F. Easton,et al.  The genetics of breast and ovarian cancer. , 1995, British Journal of Cancer.

[31]  J. Freudenheim,et al.  Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. , 1995, Cancer research.

[32]  L Piana,et al.  Age as a prognostic factor in breast cancer: Relationship to pathologic and biologic features , 1995, International journal of cancer.

[33]  D. Neuberg,et al.  Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  M. Gerretsen,et al.  A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. , 1990, British Journal of Cancer.